Drug intelligence / Profile preview

bempegaldesleukin + pembrolizumab

Development stage: Discontinued
Lead developer: Nektar Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

Bempegaldesleukin (BEMPEG) + pembrolizumab is an investigational combination immunotherapy. BEMPEG is a CD122-preferential IL-2 pathway agonist engineered to deliver controlled and sustained IL-2 signaling with reduced toxicity. It consists of recombinant human IL-2 conjugated with polyethylene glycol (PEG) molecules that reduce affinity for CD25, leading to preferential activation of T effector cells and NK cells over T regulatory cells. Pembrolizumab (KEYTRUDA) is a PD-1 immune checkpoint inhibitor. The combination aims to provide complementary immune-activating mechanisms to enhance antitumor responses.

Brand names: Keytruda
Other names: BEMPEG + pembrolizumabBEMPEG + KEYTRUDA

Targets

IL2RB (IL-2 receptor beta chain)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on bempegaldesleukin + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bempegaldesleukin + pembrolizumab.

Explore the full profile